United States-based Parnell Pharmaceuticals has announced that it has developed Nomovid, claimed to be the first antiviral nasal spray in the United States, it was reported on Wednesday.
The company says that the product is easy-to-use, low-cost and can be offered over-the-counter for consumers.
The product is based on a substance licensed by the company from New Mexico Tech University to treat drug-resistant bacteria and fungi such as MRSA and Candida auris. Parnell had been taking the necessary steps to enter the FDA approval process for the MRSA indication, until it reportedly saw very positive results against COVID-19. The company is now filing for the COVID-19 indication instead.
Clene Inc closes registered direct offering of common stock to existing shareholders
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis